Vipin Garg, Altimmune CEO
March 21, 2023 11:24 AM EDT
R&D

Al­tim­mune’s shares halved af­ter in­ter­im look at PhII weight loss drug da­ta

Kyle LaHucik

Senior Reporter

Al­tim­mune’s at­tempt to catch up to No­vo Nordisk and Eli Lil­ly’s GLP-1 drugs hit an in­vestor snag Tues­day af­ter the biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times